Collaborative research on managing Type 1 Diabetes in China
Chinese Alliance for Type 1 Diabetes Multi-center Collaborative Research
This study is trying to improve the care and treatment of people with Type 1 Diabetes in China by using new technology and education to help manage their condition better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Sex | All |
| Sponsor | Second Xiangya Hospital of Central South University Academic / other |
| Locations | 1 site (Changsha, Hunan) |
| Trial ID | NCT04096794 on ClinicalTrials.gov |
What this trial studies
The China Alliance for Type 1 Diabetes (CAT1D) aims to enhance the diagnosis and treatment of Type 1 Diabetes through a multi-center collaborative approach. This initiative focuses on building a comprehensive electronic database of Type 1 Diabetes patients and their relatives, while also studying the occurrence and development of diabetes-related complications in China. The project includes structured education and management strategies tailored to the Chinese population, utilizing mobile health and AI technologies to improve patient outcomes. By establishing a standardized treatment plan based on evidence, the study seeks to reduce complications and enhance the quality of care for individuals with Type 1 Diabetes.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with Type 1 Diabetes who are capable of using smartphones and mobile applications.
Not a fit: Patients with mental disorders or those who do not meet the criteria for Type 1 Diabetes may not benefit from this study.
Why it matters
Potential benefit: If successful, this initiative could significantly improve the management and outcomes of Type 1 Diabetes patients in China.
How similar studies have performed: While similar approaches have been explored, this study represents a novel integration of mobile health and AI technologies in the management of Type 1 Diabetes in China.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Individuals diagnosed with Type 1 Diabetes according to the 1999 World Health Organization report * Written informed consent from the patient or family representative; * Individuals who own smartphone and are capable of using wechat or apps Exclusion Criteria: * Non-t1dm patients with autoimmune polyendocrine adenopathy syndrome (APS) are the first disease * With mental disorders * Have any other condition or disease that may hamper from compliance with the protocol or complication of the trial
Where this trial is running
Changsha, Hunan
- Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University — Changsha, Hunan, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.